RxDoctor Payments Data

Kusi Fordjour, MD

Internal Medicine · Desoto, TXNPI 1780623074

Payments from drug & device makers

$2,158in general payments, 2019–2025

Across 102 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$385
  • Novo Nordisk$301
  • Boehringer Ingelheim$197
  • Abbott$162
  • Bayer$156
  • Dexcom, Inc.$114
  • plus $843 from 16 others

What the payments were for

  • Food & beverage$2,158100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,158 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$50,277
Medicare patients
86
Services billed
549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide104$167,456
RybelsusSemaglutide60$117,151
JardianceEmpagliflozin78$104,572
OzempicSemaglutide22$34,800
FarxigaDapagliflozin Propanediol25$31,760
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$20,408
JanuviaSitagliptin Phosphate16$19,436
EliquisApixaban19$17,114
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt13$7,182
Breo ElliptaFluticasone/Vilanterol12$4,513
Nifedipine ErNifedipine131$4,040
Gabapentin169$3,955
SymbicortBudesonide/Formoterol Fumarate15$3,422
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,065
Albuterol Sulfate HfaAlbuterol Sulfate106$2,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$103$167,456104 claims
Novo NordiskRybelsus, Ozempic, Novolog Mix 70-30$301$154,01193 claims
Boehringer IngelheimJardiance$197$104,57278 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$385$55,58973 claims
MerckJanuvia$81$19,43616 claims
PfizerEliquis$32$17,11419 claims
GSKBreo Ellipta$79$4,51312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Desoto

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →